WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406661
CAS#: 1431697-74-3 (free base); 1431697-78-7 (HCl).
Description: CAL-130 is a potent and selective PI3K gamma and delta inhibitor with potential anticancer activity. Constitutive phosphoinositide 3-kinase (PI3K)/Akt activation is common in T cell acute lymphoblastic leukemia (T-ALL). Although four distinct class I PI3K isoforms (α, β, γ, δ) could participate in T-ALL pathogenesis, none has been implicated in this process. In the absence of PTEN phosphatase tumor suppressor function, PI3Kγ or PI3Kδ alone can support leukemogenesis, whereas inactivation of both isoforms suppressed tumor formation.
MedKoo Cat#: 406661
Name: CAL-130
CAS#: 1431697-74-3 (free base); 1431697-78-7 (HCl).
Chemical Formula: C23H22N8O
Exact Mass: 426.19166
Molecular Weight: 426.48
Elemental Analysis: C, 64.77; H, 5.20; N, 26.27; O, 3.75
CAL-130, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Synonym: CAL130; CAL 130; CAL-130.
IUPAC/Chemical Name: (S)-2-(1-((2-amino-7H-purin-6-yl)amino)ethyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one
InChi Key: PUYVJBBSBPUKBT-AWEZNQCLSA-N
InChi Code: InChI=1S/C23H22N8O/c1-12-7-4-5-10-16(12)31-21(28-15-9-6-8-13(2)17(15)22(31)32)14(3)27-20-18-19(26-11-25-18)29-23(24)30-20/h4-11,14H,1-3H3,(H4,24,25,26,27,29,30)/t14-/m0/s1
SMILES Code: O=C1N(C2=CC=CC=C2C)C([C@@H](NC3=C4NC=NC4=NC(N)=N3)C)=NC5=C1C(C)=CC=C5
The following data is based on the product molecular weight 426.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Subramaniam PS, Whye DW, Efimenko E, Chen J, Tosello V, De Keersmaecker K, Kashishian A, Thompson MA, Castillo M, Cordon-Cardo C, Davé UP, Ferrando A, Lannutti BJ, Diacovo TG. Targeting nonclassical oncogenes for therapy in T-ALL. Cancer Cell. 2012 Apr 17;21(4):459-72. doi: 10.1016/j.ccr.2012.02.029. PubMed PMID: 22516257.
Related:
1431697-74-3 (free base)
1431697-78-7 (HCl).